- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
December 3rd, 2003
Designing therapeutic drugs to treat degenerative diseases such as Alzheimer’s and Lou Gehrig’s is challenging enough. But getting them past the protective blood-brain barrier and into brain tissue can prove mind-boggling.
Two biotechnology companies that specialize in nanoscale pharmaceuticals signed deals recently that may allow them to accomplish both feats. Advectus Life Sciences Inc. in Vancouver and C Sixty Inc. in Houston announced partnerships that could pave the way for therapies for Alzheimer’s, Lou Gehrig’s disease and other life-threatening conditions.
|Related News Press|
Pixel-array quantum cascade detector paves the way for portable thermal imaging devices: Research team from TU-Wien Center for Micro- and Nanostructures have developed a new 'cooler' sensing instrument thereby increasing energy-efficiency and enhancing mobility for diagnostic tes July 28th, 2016
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016